

1653
4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

IKONOMIDOU, Hrissanthi

RECEIVED

AUG 22 2001

TECH CENTER 1600/2900

Serial No. : 09/830,354

Filed : 25 April 2001

Title: NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

CITED MATERIALS

Applicant(s) wish to disclose the following information, listed in the attached form PTO-1449.

Copies of materials listed but not attached were cited in parent application Serial No. _____.

Copies of materials listed but not attached were cited in an International Search Report dated 14 February 2000; receipt of any International Search Report and copies of references were confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed 14 June 2001.

Copies of materials listed and attached were cited in a communication from a foreign patent office in a counterpart foreign application.

Also included are the pending U.S. applications listed below, copies of which are attached:

FEES

No fee is required for this Information Disclosure Statement because:

This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;

This Information Disclosure Statement is being filed before the mailing of a first action on the merits;

This Information Disclosure Statement is being filed before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.

- A check is attached: This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).
- A check is attached: This Information Disclosure Statement is being filed after the mailing date of a notice of allowance under § 1.311 but before the payment of the issue fee and is accompanied by the fee set forth in § 1.17(p) and a certification below.

CERTIFICATION

- Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT


If appropriate, attached is a check in the amount of \$_____. However, the Commissioner is hereby authorized to charge fees under 37 CFR 1.16 and 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,


Jennifer Branigan
Registration No.40,921
Patent Agent

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Date: 20 August 2001

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DKT. NO. HRISS-1	SERIAL NO. 09/830354
 OPI INFORMATION DISCLOSURE STATEMENT BY APPLICANT AUG 20 2001 <small>(Use several sheets if necessary)</small>				APPLICANT IKONOMIDOU	
				FILING DATE April 25, 2001	GROUP

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
AA	4885171	12/5/1989	SURENDRA SEHGAL N			
AB						
AC						
AD						
AE						AUG 22 2001
AF						
AG						TECH CENTER 1600/2900

RECEIVED**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
AM	0778023	6/11/1997	EP				
AN	0432994	6/19/1991	EP				
AO							
AP							
AQ							
AR							
AS							
AT							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AU	S.BEN-ELIYAHU: "The NMDA receptor antagonist MK-801 blocks nonopiod stress induced analgesia and decreases tumor metastasis in the rat" PROCEEDINGS OF THE WESTERN PHARMACOLOGY SOCIETY, vol 36, 1993, pg 293-298
AV	N.SEILER: "Polyamine sulfonamides with NMDA antagonist properties are potent calmodulin antagonists and cytotoxic agents" INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY vol 30 no. 3 March 1998 pg 393-406
AW	K.IGARASHI: "Antagonist properties of polyamines and bis(ethyl)polyamines at N-methyl-D-aspartate receptors" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS vol 272 no.3, 1995, pg 1101-1109
AX	I.CHAUDIEU: "D-Aspartic Bets Hydroxymate (DAH) an Antitumoral Drug, Acts on n-Methyl-D-Aspartate Receptors in Rat Brain" J.NEUROCHEM vol 61, 1993 supplement pg S255
AY	KYAMADA: "Clinical and experimental studies on the antileukemic action of L-asparaginase" COLLOQ.INT.CENT.NAT.RECH.SCI. no. 197, 1971, pg 311-322
AZ	
Examiner	
Date Considered	